Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

Frey, Sarah; Connolly, Cynthia; Chiang, Teresa Po‐Yu; Teles, Mayan; Alejo, Jennifer L; Boyarsky, Brian J.; Christopher‐Stine, Lisa; Werbel, William A; Segev, Dorry L.; Paik, Julie J

doi:10.1016/s2665-9913(21)00282-4

Cited by 11 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These response rates are clearly inferior to those published for vaccinated patients treated with anti‐CD20 mAbs for non‐malignant diseases. 6 , 7 , 8 , 9 , 13 , 14 , 15 Our results shown in Figure 2 for MS are in line with those published by others, and reports on patients with immune‐mediated glomerulonephritis and systemic rheumatological diseases using rituximab. 6 , 7 , 8 , 9 …”

Section: Discussionsupporting

confidence: 92%

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination

et al. 2022

View full text Add to dashboard Cite

Summary B‐cell depletion induced by anti‐cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccination, but effects on CD8 T‐cell responses are unknown. Here, we investigated humoral and CD8 T‐cell responses following two vaccinations in patients with lymphoma undergoing anti‐CD20‐mAb therapy as single agent or in combination with chemotherapy or other anti‐neoplastic agents during the last 9 months prior to inclusion, and in healthy age‐matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor‐binding domain of the SARS‐CoV‐2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T‐cell responses against prevalent human leucocyte antigen (HLA) class I SARS‐CoV‐2 epitopes were determined by peptide‐HLA multimer analysis. Strong CD8 T‐cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS‐CoV‐2‐vaccinated, anti‐CD20‐treated patients with lymphoma, their CD8 T‐cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B‐cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID‐19) vaccines, and development of vaccines aimed at eliciting T‐cell responses to non‐Spike epitopes might provide improved protection.

show abstract

Section: Discussionsupporting

confidence: 92%

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Our findings are consistent with existing studies examining the kinetics of anti-RBD antibodies after vaccination in patients with IBD (6), as well as other immunosuppressed populations (7,10,11). Of note, the clinical impact of quantitatively detectable, but lower antibody levels, is unclear.…”

Section: Discussionsupporting

confidence: 90%

Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

INTRODUCTION:The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.METHODS:We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.RESULTS:Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.DISCUSSION:Larger longitudinal studies are required to define the response in IBD population and its clinical impact.

show abstract

“…Antibody response following SARS-CoV-2 vaccination has been shown for up to 6 months in immunocompetent populations. 1 Although we previously described overall stability of SARS-CoV-2 antibody titres at 3 months in patients with rheumatic and musculoskeletal disease, 2 , 3 few longitudinal data exist beyond 3 months in immunosuppressed patients with rheumatic and musculoskeletal disease. Additionally, with the US Food and Drug Administration authorisation of third vaccine doses for immunosuppressed individuals, 4 , 5 the optimal timing for such doses in this patient group remains unknown.…”

mentioning

confidence: 99%

“…All of these participants reported antimetabolite use, which might suggest a delayed antibody response in patients on some lymphodepleting therapies and is consistent with previous findings. 3 , 10 …”

mentioning

confidence: 99%

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

Frey

Chiang

Connolly

et al. 2022

The Lancet Rheumatology

Self Cite

View full text Add to dashboard Cite

Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination

Cited by 11 publications

References 6 publications

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination

Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

Contact Info

Product

Resources

About